Jun 13, 2020
EHA25Virtual: Adult Patients With Sickle Cell Disease May Be at Increased Risk of Adverse Outcomes From COVID-19
Jun 04, 2020
Protagonist Therapeutics to Present at the 25th European Hematology Association (EHA) Annual Congress
Jun 01, 2020
Aruvant Appoints Dr. Palaniappan as Chief Technology Officer
May 11, 2020
Aruvant Appoints Joseph McIntosh, M.D. as Chief Medical Officer
Feb 26, 2020
Thalassemia Treatment Market Outlook to 2025 by Treatment Type, Disease Type, End-user and Geography
Jan 22, 2020
Aruvant Receives Orphan Drug Designation for ARU-1801 for the Treatment of Sickle Cell Disease
Dec 03, 2019
Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia
Nov 08, 2019
FDA approves first therapy to treat patients with rare blood disorder
Oct 30, 2019
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Polycythemia Vera
Aug 13, 2019
A Platform for Screening Drugs To Treat Sickle Cell Disease Now Offered by ReachBio Research Labs
Jul 08, 2019
Global Carrier Screening Market: Focus on Product Type, Technology Type,18 Countries Data, Autosomal Recessive Disorders, Industry Insights, and Competitive Landscape - Analysis and Forecast, 2019-2029
Jun 18, 2019
Arix Bioscience plc: Imara Presents initial Phase 2a data for IMR-687
May 29, 2019
Cooley's Anemia Foundation Celebrates a New Era of Hope for Thalassemia Patients Annual Gala Honors Global Foundation Leadership & Patient Activist
Mar 18, 2019
Arix Bioscience plc: Arix Co-leads $63 Million Series B Investment Round for Imara
Jan 09, 2019
Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta Thalassemia
Dec 05, 2018
Protagonist Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
Dec 03, 2018
Aruvant Sciences Presents Data from Ongoing Clinical Study of Lentiviral Gene Therapy RVT-1801 for Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology
Dec 01, 2018
Major Trials Show Benefits of New Therapy Regimens for Cancer and Blood Disorders
Nov 26, 2018
Roivant Launches Aruvant Sciences and Roivant Foundation in Partnership with Cincinnati Children's Hospital Medical Center
Nov 06, 2018
Protagonist Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update